For PFIZER to make PALBOCICLIB drug available for 6 year old with soft tissue cancer who has exhausted all other treatment options
Eva is 6 ½ years old. She has been battling rhabdomyosarcoma (soft tissue cancer) since she was 4 years old. She has endured numerous treatments and amputation of her left arm and shoulder. Despite everything she continues to go to school regularly, plays hockey for a champion team, and does almost everything a child her age should be doing. However, despite coping extremely well with every treatment and procedure thrown her way, some tumours have disappeared and somecontinue to grow. A recent genetic profiling report indicated she has loss of the CDKN2A/B gene. This report indicates that tumours that show loss of the CDKN2A/B gene are sensitive to CDK4/6 inhibitors. Eva has exhausted all treatment options within the realm of paediatric cancer world. A CDK4/6 inhibitor called PALBOCICLIB produced by PFIZER is currently in extensive adult trials as this is a billion dollar drug. There are no trials for its use in children. Pfizer have refused Eva’s oncologist’s request for this drug. With no treatment Eva will die.
Eva’s family are hoping that PFIZER will reconsider making PALBOCICLIB available as it appears their only hope at this point. Eva needs a miracle!